Immediate type allergy to latex is still a widespread problem. Latex-allergic patients undergoing diagnostic and operative medical procedures are at risk of potentially life-threatening reactions. Accurate diagnostic methods are therefore crucial. The aim of this retrospective study was to discriminate between sensitization and relevant allergy to latex based on an easy and suitable diagnostic approach. In 14 patients with clinical symptoms and 27 controls, latex skin prick tests (SPT), IgE against latex (CAP) and serological component resolved specific latex-allergen determination (Hev b1, b3, b5, b6, b7, b8, b9, b10, b11) based on ImmunoCAP ISAC were performed. SPT correlated very well with clinically manifest latex-allergy demonstrating a high specificity (95%) (and a low sensitivity). However, CAP levels to crude latex could not safely discriminate between purely sensitized and latex-allergic patients. The majority of patients mono-sensitized to the latex profilin Hev b8 did not suffer from any relevant symptoms upon contact with latex. However, in two patients with latex-allergy diagnosed by elevated specific IgE only sensitized against Hev b8, additional sensitization to carbohydrate cross-reactive determinants (CCD) was found. In the case of positive serum IgE against latex and negative SPT, component-resolved diagnosis including IgE against specific latex-proteins, specially Hev b8, and carbohydrate cross-reactive determinants (CCD) is a useful tool to discriminate between latex-sensitization and latex-allergy.

Although rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of acute retinal necrosis.

BackgroundB cell depleting therapy is widely used for lymphoproliferative diseases and immune-mediated disorders, including mucous membrane pemphigoid. The latter is an autoimmune blistering disease affecting predominantly the mucosae potentially associated with devastating complications.MethodsA 71-year-old patient with severe mucous membrane pemphigoid involving ocular, oral pharyngeal and laryngeal involvement is described. To control the disease, the patient was given rituximab therapy in combination with oral corticosteroids. He subsequently experienced an epithelial herpes simplex virus keratitis in one eye and 3 months later in his fellow eye. Topical treatment with ganciclovir resulted in prompt recovery.ResultsFor the first time, a correlation between rituximab and bilateral epithelial herpes simplex virus keratitis is described.ConclusionsAlthough rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of herpes simplex virus keratitis.